GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017, and that was without much contribution from its newly launched shingles vaccine, Shingrix.Original Article
GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.